• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23356 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Drug-eluting stents in coronary heart disease]
2014     The Swedish Council on Health Technology Assessment (SBU) [Drug-eluting stents in coronary arteries]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Drug-eluting balloon for the treatment of coronary stenosis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon dilation catheter for the transurethral treatment of urethral strictures - Assessment according to §137h Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon dilation catheter for the transurethral treatment of urethral strictures - Assessment according to §137h Social Code Book V - Third addendum to Commission H20-02]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon dilatation catheter for transurethral treatment of urethral strictures - Addendum to commission H20-02]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon catheter for the transurethral treatment of urethral strictures - Second addendum to commission H20-02]
2010     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug treatment of hypertension - update search (rapid report)]
2016     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Drug treatment of children with respiratory tract infections - a scoping review]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Drug treatment of ADHD (Attention Deficit/Hyperactivity Disorder) in adults in Germany]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug combination of emtricitabine, rilpivirine and tenofovir disoproxil (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Drotrecogin alfa in the treatment of severe sepsis]
2011     Haute Autorite de sante (HAS) [Dressings: indications and recommended uses]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Second addendum to commission A21-84]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V - Addendum]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine (HIV infection in adolescents) - Benefit assessment according to §35a Social Code Book V]
2009     The Swedish Council on Health Technology Assessment (SBU) [Dopaminergic agents in treating restless legs syndrome]
1999     Basque Office for Health Technology Assessment (OSTEBA) [Domiciliary oxygen therapy]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/lamivudine (HIV infection) - Second Addendum to Commission A19-55]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/lamivudine (HIV infection) - Addendum to Commission A19-55]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/abacavir/lamivudine (HIV infection in children) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/abacavir/lamivudine - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dolutegravir, Abacavir and Lamivudine (Triumeq®) in HIV infection]
2020     National Committee for Technology Incorporation (CONITEC) [Dolutegravir for the treatment of pregnant women living with HIV]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV infection) - Addendum to commission A17-11]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV infection in children aged >= 4 weeks to < 6 years) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2002     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [DMARD therapy of rheumatoid arthritis, systematic review of the clinical and economic literature]
2011     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Dissemination of HTA products. New lines of action]
2020     National Authority for Assessment and Accreditation in Healthcare (INEAS) [Disinfection chambers/tunnels in the context of COVID-19 pandemic]
2013     Norwegian Knowledge Centre for the Health Services (NOKC) [Discharging patients with chronic disease: effect of various forms of cooperation between hospital and the community health service]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Diroximel fumarate (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Direct-acting oral anticoagulants for postoperative thrombosis prophylaxis]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dipyridamole and aspirin for secondary prevention after stroke or TIA]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Dipeptidyl-peptidase 4 inhibitors in patients with prediabetes or metabolic syndrome]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dipeptidyl peptidase-4 inhibitors as treatment for diabetes mellitus]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Dipeptidyl peptidase-4 (dpp4) inhibitors in diabetes mellitus]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Diode laser vaporization in benign prostatic hyperplasia]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dinutuximab for patients with high-risk neuroblastoma]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dimethyl fumarate (relapsing remitting multiple sclerosis) –Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dimethyl fumarate (psoriasis) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dimethyl fumarate - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2012     Andalusian Health Technology Assessment Area (AETSA) [Digital tomosynthesis of the breast]
2018     Andalusian Health Technology Assessment Area (AETSA) [Digital tomosynthesis in breast cancer: meta-analysis]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Digital tomosynthesis for the diagnosis of breast cancer]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Digital tomosynthesis for breast cancer]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Digital screening mammography. Critical analysis of the article by Chiarelli (2013) and literature review]
2011     Basque Office for Health Technology Assessment (OSTEBA) [Digital mammograms in breast cancer screening. Assessment of their efficiency and inclusion in the Early Breast Cancer Detection Programme of the Basque Country]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Digital interventions - Evidence report on the S3 guideline "Cannabis-related disorders"]
2012     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Digital hearing aid in comparison with analog hearing aid for presbycusis: evaluation of the clinical effectiveness and the cost-effectiveness]
2022     Health Sciences Institute in Aragon (IACS) [Digital dermatoscopy]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Digital dermatoscopy for dysplastic nevi]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Digital breast tomosynthesis]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Digital Breast Tomosynthesis]
2010     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Differential diagnostic of the burnout syndrome]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Different antihypertensive drugs as first-line therapy in patients with essential hypertension]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Difelikefalin (pruritus) - Benefit assessment according to §35a Social Code Book V]
2013     The Swedish Council on Health Technology Assessment (SBU) [Dietary treatment of obesity]
2010     The Swedish Council on Health Technology Assessment (SBU) [Dietary treatment of diabetes]
2000     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Dietary guidance in the primary health care sector (co-funded by DIHTA)]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Dielectric radiofrequency for the treatment of primary hyperhidrosis and bromhidrosis]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Diamine oxidase activity test for histamine intolerance]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Dialysis in chronic renal failure - a health technology assessment]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Diagnostics and treatment of provoked vestibulodynia]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Diagnostic value of novel biomarkers in patients with chest pain of suspected cardiac origin]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Diagnostic value of an innovative non-invasive diagnostic to determine the grade of atherosclerosis before sternotomy in patients scheduled for cardiac surgery]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Diagnostic usefulness of brain FDG-PET for Alzheimer's dementia]
2019     National Committee for Technology Incorporation (CONITEC) [Diagnostic tests for thrombophilia in pregnancy]
2002     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Diagnostic radiology using transportable equipment]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Diagnostic precision with liquid biopsy for asymptomatic ovarian cancer]
2008     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Diagnostic performance of techniques used for HER-2 testing in breast cancer]
2009     Andalusian Health Technology Assessment Area (AETSA) [Diagnostic performance of digital mammography in breast cancer screening]
2008     Andalusian Health Technology Assessment Area (AETSA) [Diagnostic performance of clinical prediction models for pulmonary embolism]
2014     The Swedish Council on Health Technology Assessment (SBU) [Diagnostic imaging in the staging of prostate cancer]
2014     The Swedish Council on Health Technology Assessment (SBU) [Diagnostic imaging in suspected prostate cancer]
2008     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Diagnostic evaluation and treatment of dementia – a health technology assessment]
2005     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic effectiveness, security and clinical usefulness of capsule endoscopy in the diagnosis of small bowel disorders]
2018     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Diagnostic effectiveness and safety of elastography in liver fibrosis]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Diagnostic colon evaluation in patients with suspected colorectal neoplasia or at high risk of colorectal neoplasia - a comparison of double contrast barium enema (DCBE), CT colonography and colonoscopy]
2000     Basque Office for Health Technology Assessment (OSTEBA) [Diagnostic and therapeutic approach to non complex duodenal ulcer]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic and clinical utility of impulse oscillometry for use in patients with difficulty performing spirometry]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Diagnostic accuracy of anti-CCP antibody test in rheumatoid arthritis: systematic review]
2004     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic accuracy and clinical usefulness of Positron Emission Tomography (PET) in breast and ovarian cancer recurrence]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Diagnosis of gestational diabetes mellitus: evaluation of the new IADPSG criteria]
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Diagnosis and treatments for epilepsy – a systematic review]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Diagnosis and treatment of obstructive sleep apnoea - a health technology assessment]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Diagnosis and treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in people with Multiple Sclerosis (MS)]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Diagnosis and treatment of chronic cerebrospinal venous insufficiency (CCSVI) for people with multiple sclerosis]
2013     The Swedish Council on Health Technology Assessment (SBU) [Diagnosis and treatment of ADHD and ASDs (autism spectrum disorders)]